Cannovex

Agoralaan Building Abis /

3590 Diepenbeek

BE

Cannovex

Foundation date

06/08/2016

Sector

#Biotechnology - other

Subsector

Therapeutic areas

Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.

Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.

Upcoming events

Latest news

  • UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa

    1 day ago

  • Company growth prompts Connected-Pathology relocation to larger laboratory facilities to accommodate increase in study capacity

    Tuesday December 6th 2022

  • Japan welcomes companies, startups and knowledge institutions from Flanders

    Friday December 2nd 2022